pargyline has been researched along with Prostatic Hyperplasia in 1 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Liu, X | 1 |
| Jiang, G | 1 |
| Chen, H | 1 |
| Guo, J | 1 |
| Weng, X | 1 |
1 other study available for pargyline and Prostatic Hyperplasia
| Article | Year |
|---|---|
Relationship between LSD1 expression and E-cadherin expression in prostate cancer.
Topics: Cadherins; Carcinoma; Cell Line, Tumor; Disease Progression; Histone Demethylases; Humans; Male; Neo | 2015 |